ClinicalTrials.gg
CompletedNCT01004614Updated Jan 28, 2021Results posted

Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet

A Phase 1 interventional study of Amlodipine and Amlodipine in Healthy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

This study is being conducted to determine if 5 mg amlodipine 3rd Orally-Disintegrating (OD) tablet (new formulation) and 5 mg amlodipine 2nd OD tablet (commercial formulation) are bioequivalent.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy;
  • (BMI) of 18 to 28 kg/m2;
  • total body weight within the range of 50 to 100 kg

Exclusion criteria

Exclusion Criteria:

  • History of regular alcohol consumption exceeding 14 drinks/week
  • Use of tobacco- or nicotine-containing products in excess of the equivalent of 10 cigarettes per day
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1

    24 subjects (12 subjects per sequence) will receive treatment A) one 5 mg amlodipine 3rd OD tablet (test) with water and treatment B) one 5 mg amlodipine 2nd OD tablet (reference) with water.

    Drug: Amlodipine

  • Active comparator
    Cohort 2

    24 subjects (12 subjects per sequence) will receive treatment C) one 5 mg amlodipine 3rd OD tablet (test) without water, and treatment D) one 5 mg amlodipine 2nd OD tablet (reference) without water

    Drug: Amlodipine

Interventions

  • 3rd OD 5 mg tablet single oral dose administered with water

  • 2nd OD 5 mg tablet single oral dose administered with water

  • 3rd OD 5 mg tablet single oral dose administered without water

  • 2nd OD 5 mg tablet single oral dose administered without water

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt)

    Area under the concentration-time curve from zero time until the last sampling time

    Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast), Area Under the Plasma Concentration-Time Curve to Infinity (AUCinf)

    AUC last = Area under the concentration versus time curve from zero time until the last measurable concentration is calculated using the trapezoidal rule. AUCinf = AUClast + (Ct / kel), where Ct is the estimated concentration at the last measurable concentration.

    Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose

  2. Apparent Terminal Elimination Phase Rate Constant (Kel)

    Estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile.

    Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose

  3. Apparent Terminal Elimination Half-Life (T-half)

    Terminal phase half-life calculated as ln(2) / kel

    Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose

  4. Mean Residence Time (MRT)

    MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from zero time to infinity calculated as AUMCinf = AUMCt + ((t x Ct) / kel) + (Ct / kel\^2). AUMCt is the area under the first moment curve from zero time to time t calculated using the trapezoidal method.

    Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose

  5. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose

07

Results

Posted Jan 4, 2012

Participant flow

Participants were screened at one center in Japan.

First Intervention
Participant flow — First Intervention
Milestone3rd OD Tablet With Water, Then 2nd OD Tablet With Water2nd OD Tablet With Water, Then 3rd OD Tablet With Water3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water2nd OD Tablet Without Water, Then 3rd OD Tablet Without Water
Started12121212
Completed12121212
Not completed0000
Washout
Participant flow — Washout
Milestone3rd OD Tablet With Water, Then 2nd OD Tablet With Water2nd OD Tablet With Water, Then 3rd OD Tablet With Water3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water2nd OD Tablet Without Water, Then 3rd OD Tablet Without Water
Started12121212
Completed12111212
Not completed0100
Withdrew: Withdrawal by subject0100
Second Intervention
Participant flow — Second Intervention
Milestone3rd OD Tablet With Water, Then 2nd OD Tablet With Water2nd OD Tablet With Water, Then 3rd OD Tablet With Water3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water2nd OD Tablet Without Water, Then 3rd OD Tablet Without Water
Started12111212
Completed12111212
Not completed0000

Outcome measures

PrimaryArea Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt)

Area under the concentration-time curve from zero time until the last sampling time

Time frame:
prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Reported as:
Mean · ng*h/mL
Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt)
ng*h/mLCohort I: 3rd OD Tablet (Test) With WaterCohort I: 2nd OD Tablet (Reference) With WaterCohort II: 3rd OD Tablet (Test) Without WaterCohort II: 2nd OD Tablet (Reference) Without Water
Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt)126.36 ± 33.16129.48 ± 39.93122.33 ± 32.59119.75 ± 28.23
Statistical analysis
  • Cohort I: 3rd OD Tablet (Test) With Water vs Cohort I: 2nd OD Tablet (Reference) With Water vs Cohort II: 3rd OD Tablet (Test) Without Water vs Cohort II: 2nd OD Tablet (Reference) Without Water · Ratios of adjusted geometric mean: 98.61 · 90% CI 93.09 to 104.46Parameter estimate = ratio (%) (test/reference) of adjusted geometric means.
  • Cohort I: 3rd OD Tablet (Test) With Water vs Cohort I: 2nd OD Tablet (Reference) With Water vs Cohort II: 3rd OD Tablet (Test) Without Water vs Cohort II: 2nd OD Tablet (Reference) Without Water · Ratios of adjusted geometric mean: 101.29 · 90% CI 97.28 to 105.45Parameter estimate = ratio (%) (test/reference) of adjusted geometric means.
PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLCohort I: 3rd OD Tablet (Test) With WaterCohort I: 2nd OD Tablet (Reference) With WaterCohort II: 3rd OD Tablet (Test) Without WaterCohort II: 2nd OD Tablet (Reference) Without Water
Maximum Observed Plasma Concentration (Cmax)2.70 ± 0.5132.74 ± 0.6502.48 ± 0.4702.45 ± 0.409
Statistical analysis
  • Cohort I: 3rd OD Tablet (Test) With Water vs Cohort I: 2nd OD Tablet (Reference) With Water vs Cohort II: 3rd OD Tablet (Test) Without Water vs Cohort II: 2nd OD Tablet (Reference) Without Water · Ratios of adjusted geometric mean: 99.30 · 90% CI 92.28 to 106.28Parameter estimate = ratio (%) (test/reference) of adjusted geometric means.
  • Cohort I: 3rd OD Tablet (Test) With Water vs Cohort I: 2nd OD Tablet (Reference) With Water vs Cohort II: 3rd OD Tablet (Test) Without Water vs Cohort II: 2nd OD Tablet (Reference) Without Water · Ratios of adjusted geometric mean: 100.84 · 90% CI 95.93 to 106.00Parameter estimate = ratio (%) (test/reference) of adjusted geometric means.
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast), Area Under the Plasma Concentration-Time Curve to Infinity (AUCinf)

AUC last = Area under the concentration versus time curve from zero time until the last measurable concentration is calculated using the trapezoidal rule. AUCinf = AUClast + (Ct / kel), where Ct is the estimated concentration at the last measurable concentration.

Time frame:
prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Reported as:
Mean · ng*h/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast), Area Under the Plasma Concentration-Time Curve to Infinity (AUCinf)
ng*h/mLCohort I: 3rd OD Tablet (Test) With WaterCohort I: 2nd OD Tablet (Reference) With WaterCohort II: 3rd OD Tablet (Test) Without WaterCohort II: 2nd OD Tablet (Reference) Without Water
AUClast124.14 ± 33.96127.36 ± 40.91121.05 ± 33.76118.27 ± 29.43
AUCinf142.87 ± 43.20145.22 ± 49.19140.41 ± 42.18138.14 ± 34.10
SecondaryApparent Terminal Elimination Phase Rate Constant (Kel)

Estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile.

Time frame:
prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Reported as:
Mean · L/h
Apparent Terminal Elimination Phase Rate Constant (Kel)
L/hCohort I: 3rd OD Tablet (Test) With WaterCohort I: 2nd OD Tablet (Reference) With WaterCohort II: 3rd OD Tablet (Test) Without WaterCohort II: 2nd OD Tablet (Reference) Without Water
Apparent Terminal Elimination Phase Rate Constant (Kel)0.0174 ± 0.00310.0179 ± 0.00350.0162 ± 0.00410.0156 ± 0.0031
SecondaryApparent Terminal Elimination Half-Life (T-half)

Terminal phase half-life calculated as ln(2) / kel

Time frame:
prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Reported as:
Mean · hour
Apparent Terminal Elimination Half-Life (T-half)
hourCohort I: 3rd OD Tablet (Test) With WaterCohort I: 2nd OD Tablet (Reference) With WaterCohort II: 3rd OD Tablet (Test) Without WaterCohort II: 2nd OD Tablet (Reference) Without Water
Apparent Terminal Elimination Half-Life (T-half)41.45 ± 9.7640.27 ± 8.4845.04 ± 10.1646.20 ± 8.85
SecondaryMean Residence Time (MRT)

MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from zero time to infinity calculated as AUMCinf = AUMCt + ((t x Ct) / kel) + (Ct / kel\^2). AUMCt is the area under the first moment curve from zero time to time t calculated using the trapezoidal method.

Time frame:
prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Reported as:
Mean · hour
Mean Residence Time (MRT)
hourCohort I: 3rd OD Tablet (Test) With WaterCohort I: 2nd OD Tablet (Reference) With WaterCohort II: 3rd OD Tablet (Test) Without WaterCohort II: 2nd OD Tablet (Reference) Without Water
Mean Residence Time (MRT)61.29 ± 13.5559.77 ± 11.9966.18 ± 14.1067.33 ± 11.90
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hourCohort I: 3rd OD Tablet (Test) With WaterCohort I: 2nd OD Tablet (Reference) With WaterCohort II: 3rd OD Tablet (Test) Without WaterCohort II: 2nd OD Tablet (Reference) Without Water
Time to Reach Maximum Observed Plasma Concentration (Tmax)8 (4 to 12)8 (4 to 12)8 (6 to 12)8 (6 to 12)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort I: 3rd OD Tablet (Test) With Water—0/23 (0%)7/23 (30.4%)
Cohort I: 2nd OD Tablet (Reference) With Water—0/24 (0%)6/24 (25%)
Cohort II: 3rd OD Tablet (Test) Without Water—0/24 (0%)2/24 (8.3%)
Cohort II: 2nd OD Tablet (Reference) Without Water—0/24 (0%)3/24 (12.5%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCohort I: 3rd OD Tablet (Test) With WaterCohort I: 2nd OD Tablet (Reference) With WaterCohort II: 3rd OD Tablet (Test) Without WaterCohort II: 2nd OD Tablet (Reference) Without Water
HeadacheNervous system disorders2/231/240/241/24
Abdominal discomfortGastrointestinal disorders1/230/240/240/24
ToothacheGastrointestinal disorders1/231/240/240/24
PharingitisInfections and infestations1/230/240/240/24
Muscular weaknessMusculoskeletal and connective tissue disorders1/230/240/240/24
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders1/231/240/240/24
Oropharyngeal disconfortRespiratory, thoracic and mediastinal disorders1/231/240/240/24
DiarrhoeaGastrointestinal disorders0/230/241/240/24
StomatitisGastrointestinal disorders0/230/240/241/24
Blood bilirubin increasedInvestigations0/231/240/240/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)3rd OD Tablet With Water, Then 2nd OD Tablet With Water2nd OD Tablet With Water, Then 3rd OD Tablet With Water3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water2nd OD Tablet Without Water, Then 3rd OD Tablet Without WaterTotal
Mean33.8 ± 10.732.4 ± 11.137.3 ± 9.037.8 ± 12.133.1 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)3rd OD Tablet With Water, Then 2nd OD Tablet With Water2nd OD Tablet With Water, Then 3rd OD Tablet With Water3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water2nd OD Tablet Without Water, Then 3rd OD Tablet Without WaterTotal
Female00000
Male1212121248
08

Study locations

1 site
  • Pfizer Investigational Site
    Minato-ku, Tokyo, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2009
First posted
Oct 30, 2009
Start
Nov 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Jan 4, 2012
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01004614
Responsible party
Sponsor
First posted
Oct 30, 2009
Start date
Nov 2009
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Jan 4, 2012
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion